Abstract
The EICESS-92 Trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma. Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not.
Publication types
-
Clinical Trial, Phase III
-
Randomized Controlled Trial
-
Comment
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / administration & dosage
-
Dactinomycin / administration & dosage
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Follow-Up Studies
-
Humans
-
Ifosfamide / administration & dosage
-
Neoplasm Metastasis
-
Radiography
-
Sarcoma, Ewing / diagnostic imaging
-
Sarcoma, Ewing / drug therapy*
-
Sarcoma, Ewing / pathology
-
Time Factors
-
Treatment Outcome
-
Tumor Burden / drug effects
-
Vincristine / administration & dosage
Substances
-
Dactinomycin
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Ifosfamide